Kangpu Completed Bridging Clinical Study of KPG-818 in China

2024-09-21 Kangpu Biopharmaceuticals HaiPress

HEFEI,China,Sept. 20,2024 -- Kangpu Biopharmaceuticals,a clinical-stage company based in Hefei,announced today that the Company has successfully completed a bridging clinical study of KPG-818 in healthy subjects in China.

The randomized,double-blind,placebo-controlled,and food effects (FE) study aimed to assess the safety and tolerability of multiple oral doses of KPG-818 in male and female healthy participants over a treatment period of 14 days and a follow-up period of 4 weeks,to characterize the single and multiple oral dose pharmacokinetics (PK) of KPG-818,and to select dosing regimens of KPG-818 for future clinical trials. A total of 30 participants were randomized to three escalating cohorts (n=10 each; 8 KPG-818,2 placebo) receiving 0.15 mg,0.6 mg,2 mg or placebo once daily. In the FE cohort,12 participants received single dose of 0.6 mg KPG-818 with and without food.

KPG-818 is well tolerated in healthy subjects. No serious adverse events (SAEs) were reported. The most common AEs were grades 1-2 of pruritus or rash.

Close to linear PK of KPG-818 was observed in the dosing range of 0.15 mg-2 mg. Similar exposure was observed for KPG-818 under fed/fasted conditions.

KPG-818 is a small molecule modulator of CRBN E3 ubiquitin ligase complex CRL4-CRBN. In the Phase Ib/IIa clinical study in SLE patients (trial ID: NCT04643067) completed in the US,KPG-818 demonstrated promising efficacy and a favorable safety and tolerability profile.

About Kangpu Biopharmaceuticals

Kangpu Biopharmaceuticals,Ltd. is a clinical-stage company focused on the discovery and development of innovative molecular glue-based therapeutics for the treatment of autoimmune diseases,solid tumors,hematologic malignancies and inflammatory disorders. Kangpu has developed a robust pipeline of potential first-in-class and best-in-class drug candidates based on proprietary technology platforms,including NeoMIDES®,gDACS®,and X-SYNERGY®.

For more information,please visit www.KangpuGroup.com

Media Contact: Florence Liu,wenjing.liu@kangpugroup.com

Disclaimer: This article is reproduced from other media. The purpose of reprinting is to convey more information. It does not mean that this website agrees with its views and is responsible for its authenticity, and does not bear any legal responsibility. All resources on this site are collected on the Internet. The purpose of sharing is for everyone's learning and reference only. If there is copyright or intellectual property infringement, please leave us a message.

Newest

1Breaking Boundaries, Investing Without Limits: CNC Aggregated Trading Platform Leading the New Era of Globalized Investments

Breaking Boundaries, Investing Without Limits: CNC Aggregated Trading Platform Leading the New Era of Globalized Investments

2Se celebra la 68ª sesión de la Comisión de Estupefacientes de las Naciones Unidas: China, un participante activo en la lucha global contra las drogas

Se celebra la 68ª sesión de la Comisión de Estupefacientes de las Naciones Unidas: China, un participante activo en la lucha global contra las drogas

3AXES TREE LLC Launches AXES USDT: Blockchain Meets Advertising

AXES TREE LLC Launches AXES USDT: Blockchain Meets Advertising

4Laika Officially Launches the MMS Token Swap Program: Premium Members Unite to Drive a New Market Era

Laika Officially Launches the MMS Token Swap Program: Premium Members Unite to Drive a New Market Era

5"Daily Get·Lottery fund trust services (formerly Cola Financial) and มิราเคิล กรุ๊ป จำกัด reached a strategic cooperation in lottery fund trust to jointly usher in a new era of sunshine in the Asia-Pacific lottery market"

"Daily Get·Lottery fund trust services (formerly Cola Financial) and มิราเคิล กรุ๊ป จำกัด reached a strategic cooperation in lottery fund trust to jointly usher in a new era of sunshine in the Asia-Pacific lottery market"

6Congratulations on Hannah Yihan Liu's works participating in the LUV International Art Exhibition!

Congratulations on Hannah Yihan Liu's works participating in the LUV International Art Exhibition!

©copyright2009-2020Fresh life